Cart
sales@molnova.com
WSB1 Degrader 1
CAS No. 2306039-66-5
WSB1 Degrader 1( —— )
Catalog No. M24048 CAS No. 2306039-66-5
WSB1 Degrader 1 is a poten and orally active WD repeat and SOCS box-containing 1 degrader. WSB1 Degrader 1 has anticancer metastatic effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 124 | In Stock |
|
| 5MG | 112 | In Stock |
|
| 10MG | 181 | In Stock |
|
| 25MG | 320 | In Stock |
|
| 50MG | 439 | In Stock |
|
| 100MG | 597 | In Stock |
|
| 200MG | 804 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWSB1 Degrader 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionWSB1 Degrader 1 is a poten and orally active WD repeat and SOCS box-containing 1 degrader. WSB1 Degrader 1 has anticancer metastatic effects.
-
DescriptionWSB1 Degrader 1 is a poten and orally active WD repeat and SOCS box-containing 1 degrader. WSB1 Degrader 1 has anticancer metastatic effects.
-
In VitroWSB1 Degrader 1 (compound 4; 0.25-2500 nM; 2-24 hours; H1299-WSB1 cells) treatment indues WSB1 degradation in time-dependent and dose-dependent manners.WSB1 Degrader 1 (compound 4) exhibits potent antimigration efficacy in both KHOS and H460 cell lines with IC50 values of 39.1 μM and 24.47 μM, respectively.WSB1 Degrader 1 (compound 4) significantly inhibits cancer cell migration under normoxia and hypoxia in KHOS cells. WSB1 Degrader 1 (5 μM) treatment elevates the levels of the RhoGDI2 protein in KHOS cells under hypoxia.The wound-healing of H1299-WSB1 cells is significantly inhibited by treating with WSB1 Degrader 1. WSB1 Degrader 1 can only block the wound-healing capability of wild-type A2780 (A2780-WT) cells but not the A2780-WSB1/KO cells. Western Blot Analysis Cell Line:H1299-WSB1 cells Concentration:0.25 nM, 2.5 nM, 25 nM, 250 nM, 2500 nM Incubation Time:2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours Result:Induced WSB1 degradation in time-dependent and dose-dependent manners.
-
In VivoWSB1 Degrader 1 (compound 4; 100 mg/kg; p.o.; daily; for 28 days) treatment can effectively inhibit the pulmonary metastasis of cancer cells.In rats, after 100 mg/kg oral dosing or 160 mg/kg intraperitoneal dosing of WSB1 Degrader 1 (compound 4), the two ways of administration are observed with quick absorption (Tmax), but the former dosing displayed a fast clearance (T1/2). Moreover, Cmax and AUC0-t values of WSB1 Degrader 1 in oral or intraperitoneal dosing groups showed acceptable blood exposure. Animal Model:Balb/c (nu/nu) mice bearing highly metastatic 4T1 breast cancer cells.Dosage:100 mg/kg/day.Administration:p.o.; daily; for 28 days Result:Effectively inhibited the pulmonary metastasis of cancer cells.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorWSB1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2306039-66-5
-
Formula Weight334.41
-
Molecular FormulaC21H22N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:24 mg/mL?(71.76 mM;?Need ultrasonic)
-
SMILESNC1=NC(C2=CC=C(OC)C(C)=C2)=C(C3=CC=C(OC)C(C)=C3)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jinxin Che, et al. Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis. J Med Chem. 2021 Jun 1.
molnova catalog
related products
-
midesteine
Midesteine (MR-889) is a small molecule neutrophil elastase inhibitor used in the treatment of bronchitis, asthma and chronic lung disease.
-
Ganoderic acid T-Q
Ganoderic acid T-Q and TR are two inhibitors of H5N1 and H1N1 NAs.
-
Oxindole
Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
